Transcatheter mitral valve repair with MitraClip (Abbott) is largely an elective procedure. The ongoing coronavirus disease 2019 (COVID-19) pandemic has posed challenges to health care systems; in many cases elective interventions have been curtailed. Patients with severe mitral regurgitation (MR) and cardiogenic shock are high-risk surgical candidates and at risk of a poor outcome without intervention. The American College of Cardiology (ACC) and the Society of Coronary Angiography and Interventions (SCAI) recently proposed joint guidance on triage of structural heart disease (SHD) interventions during the COVID-19 pandemic. We present two illustrative cases of severe MR and cardiogenic shock that were successfully treated with MitraClip amidst the COVID-19 pandemic with good outcomes at short term follow-up.

Original languageEnglish (US)
Pages (from-to)950-953
Number of pages4
JournalCardiovascular Revascularization Medicine
Issue number8
StatePublished - Aug 2020


  • COVID-19
  • Cardiogenic shock
  • MitraClip
  • Mitral regurgitation
  • Severity of Illness Index
  • Echocardiography
  • Pandemics
  • Comorbidity
  • Heart Valve Prosthesis
  • Humans
  • Middle Aged
  • Mitral Valve/diagnostic imaging
  • Coronavirus Infections/epidemiology
  • Male
  • Shock, Cardiogenic/etiology
  • Cardiac Catheterization/methods
  • Heart Valve Prosthesis Implantation/methods
  • Pneumonia, Viral/epidemiology
  • Mitral Valve Insufficiency/diagnosis
  • Betacoronavirus

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Transcatheter Mitral Valve Repair with MitraClip for Severe Mitral Regurgitation and Cardiogenic Shock During the COVID-19 Pandemic'. Together they form a unique fingerprint.

Cite this